Patents by Inventor Kathleen A. Elias

Kathleen A. Elias has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating heart failure
    Patent number: 7605164
    Abstract: Certain substituted benzamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: February 14, 2006
    Date of Patent: October 20, 2009
    Assignee: Cytokinetics, Inc.
    Inventors: Fady Malik, Adam Lewis Tomasi, Bainian Feng, Erica Anne Kraynack, Kathleen A. Elias, Pu-Ping Lu, Whitney Walter Smith, Xiangping Qian, David J. Morgans, Jr.
  • Compounds, Compositions and Methods
    Publication number: 20090176307
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: January 5, 2009
    Publication date: July 9, 2009
    Inventors: Bradley Paul Morgan, Kathleen A. Elias, Erica Anne Kraynack, Pu-Ping Lu, Fady Malik, Alex Muci, Xiangping Qian, Whitney Walter Smith, Todd Tochimoto, Adam Lewis Tomasi, David J. Morgans, JR.
  • Compounds, compositions and methods
    Patent number: 7491826
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: July 14, 2004
    Date of Patent: February 17, 2009
    Assignee: Cytokinetics, Inc.
    Inventors: Bradley Paul Morgan, Kathleen A. Elias, Erica Anne Kraynack, Pu-Ping Lu, Fady Malik, Alex Muci, Xiangping Qian, Whitney Walter Smith, Todd Tochimoto, Adam Lewis Tomasi, David J. Morgans, Jr.
  • Compounds, compositions, and methods
    Patent number: 7399866
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: January 14, 2004
    Date of Patent: July 15, 2008
    Assignee: Cytokinetics, Inc.
    Inventors: Bradley Paul Morgan, Kathleen A. Elias, Erica Anne Kraynack, Pu-Ping Lu, Fady Malik, Alex Muci, Xiangping Qian, Whitney Walter Smith, Todd Tochimoto, Adam Lewis Tomasi, David J. Morgans, Jr.
  • Low molecular weight peptidomimetic growth hormone secretagogues
    Patent number: 7094869
    Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: August 22, 2006
    Assignee: Genentech, Inc.
    Inventors: Todd C. Somers, Kathleen A. Elias, Ross G. Clark, Robert S. McDowell, Mark S. Stanley, John P. Burnier, Thomas E. Rawson
  • Compositions and methods for treating heart failure
    Publication number: 20060173024
    Abstract: Certain substituted benzamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: February 14, 2006
    Publication date: August 3, 2006
    Applicant: Cytokinetics, Inc.
    Inventors: Fady Malik, Adam Tomasi, Bainian Feng, Erica Kraynack, Kathleen Elias, Pu-Ping Lu, Whitney Smith, Xiangping Qian, David Morgans
  • Compositions and methods for treating heart failure
    Patent number: 7053094
    Abstract: Certain substituted benzamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: January 20, 2005
    Date of Patent: May 30, 2006
    Assignee: Cytokinetics, Inc.
    Inventors: Fady Malik, Adam Lewis Tomasi, Bainian Feng, Erica Anne Kraynack, Kathleen A. Elias, Pu-Ping Lu, Whitney Walter Smith, Xiangping Qian, David J. Morgans, Jr.
  • Low molecular weight peptidomimetic growth hormone secretagogues
    Publication number: 20060063807
    Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.
    Type: Application
    Filed: May 25, 2005
    Publication date: March 23, 2006
    Applicant: Genentech, Inc.
    Inventors: Todd Somers, Kathleen Elias, Ross Clark, Robert McDowell, Mark Stanley, John Burnier, Thomas Rawson
  • Method of characterizing potential therapeutics by determining cell-cell interactions
    Publication number: 20050208471
    Abstract: A method quantitatively analyzes images of two different cell types that interact in producing and maintaining a disease state or other biological condition. The two separate cell types are exposed to an agent or stimulus suspected of influencing the biological condition (e.g., the agent might be a potential therapeutic for treating a cancer). The two different cell types are co-cultured or otherwise allowed to interact with one another before and during exposure to the agent. The images of the cells show how the agent affects the cells' phenotypes, including their viability, migration patterns, etc. The method generates a quantitative phenotype for each cell type by quantitatively analyzing the cell images via an automatic procedure. The quantitative phenotypes typically take the form of a group of scalar or vector descriptors that together provide a “fingerprint.” The descriptors may be size values, positions, morphological values, intensity distributions, etc.
    Type: Application
    Filed: January 7, 2005
    Publication date: September 22, 2005
    Inventor: Kathleen Elias
  • Compounds, compositions and methods
    Publication number: 20050159416
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: July 14, 2004
    Publication date: July 21, 2005
    Inventors: Bradley Morgan, Kathleen Elias, Erica Kraynack, Pu-Ping Lu, Fady Malik, Alex Muci, Xiangping Qian, Whitney Smith, Todd Tochimoto, Adam Tomasi, David Morgans
  • Compositions and methods for treating heart failure
    Publication number: 20050148638
    Abstract: Certain substituted benzamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: January 20, 2005
    Publication date: July 7, 2005
    Applicant: Cytokinetics, Inc.
    Inventors: Fady Malik, Adam Tomasi, Bainian Feng, Erica Kraynack, Kathleen Elias, Pu-Ping Lu, Whitney Smith, Xiangping Qian, David Morgans
  • Compositions and methods for treating heart failure
    Patent number: 6908923
    Abstract: Certain substituted benzamide derivatives of Formula I: selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: June 21, 2005
    Assignee: Cytokinetics, Inc.
    Inventors: Fady Malik, Adam Lewis Tomasi, Bainian Feng, Erica Anne Kraynack, Kathleen A. Elias, Pu-Ping Lu, Whitney Walter Smith, Xiangping Qian, David J. Morgans, Jr.
  • Compositions and methods for treating heart failure
    Publication number: 20030158233
    Abstract: Certain substituted benzamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: December 20, 2002
    Publication date: August 21, 2003
    Inventors: Fady Malik, Adam Lewis Tomasi, Bainian Feng, Erica Anne Kraynack, Kathleen A. Elias, Pu-Ping Lu, Whitney Walter Smith, Xiangping Qian, David J. Morgans,
  • Compositions and methods for treating heart failure
    Publication number: 20030158186
    Abstract: Certain substituted benzamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: December 20, 2002
    Publication date: August 21, 2003
    Inventors: Fady Malik, Adam Lewis Tomasi, Bainian Feng, Bradley Paul Morgan, Han-Jie Zhou, Kathleen A. Elias, Pu-Ping Lu, Whitney Walter Smith, Xiangping Qian, David J. Morgans,
  • Method of characterizing potential therapeutics by determining cell-cell interactions
    Patent number: 6599694
    Abstract: A method quantitatively analyzes images of two different cell types that interact in producing and maintaining a disease state or other biological condition. The two separate cell types are exposed to an agent or stimulus suspected of influencing the biological condition (e.g., the agent might be a potential therapeutic for treating a cancer). The two different cell types are co-cultured or otherwise allowed to interact with one another before and during exposure to the agent. The images of the cells show how the agent affects the cells' phenotypes, including their viability, migration patterns, etc. The method generates a quantitative phenotype for each cell type by quantitatively analyzing the cell images via an automatic procedure. The quantitative phenotypes typically take the form of a group of scalar or vector descriptors that together provide a “fingerprint.” The descriptors may be size values, positions, morphological values, intensity distributions, etc.
    Type: Grant
    Filed: December 18, 2000
    Date of Patent: July 29, 2003
    Assignee: Cytokinetics, Inc.
    Inventor: Kathleen A. Elias
  • Low molecular weight peptidomimetic growth hormone secretagogues
    Publication number: 20030139348
    Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.
    Type: Application
    Filed: August 19, 2002
    Publication date: July 24, 2003
    Applicant: Genentech, Inc.
    Inventors: Todd C. Somers, Kathleen A. Elias, Ross G. Clark, Robert S. McDowell, Mark S. Stanley, John P. Burnier, Thomas E. Rawson
  • Method of characterizing potential therapeutics by determining cell-cell interactions
    Publication number: 20020160442
    Abstract: A method quantitatively analyzes images of two different cell types that interact in producing and maintaining a disease state or other biological condition. The two separate cell types are exposed to an agent or stimulus suspected of influencing the biological condition (e.g., the agent might be a potential therapeutic for treating a cancer). The two different cell types are co-cultured or otherwise allowed to interact with one another before and during exposure to the agent. The images of the cells show how the agent affects the cells' phenotypes, including their viability, migration patterns, etc. The method generates a quantitative phenotype for each cell type by quantitatively analyzing the cell images via an automatic procedure. The quantitative phenotypes typically take the form of a group of scalar or vector descriptors that together provide a “fingerprint.” The descriptors may be size values, positions, morphological values, intensity distributions, etc.
    Type: Application
    Filed: December 18, 2000
    Publication date: October 31, 2002
    Inventor: Kathleen A. Elias
  • Method of characterizing potential therapeutics by determining cell-cell interactions
    Publication number: 20020119441
    Abstract: A method quantitatively analyzes images of two different cell types that interact in producing and maintaining a disease state or other biological condition. The two separate cell types are exposed to an agent or stimulus suspected of influencing the biological condition (e.g., the agent might be a potential therapeutic for treating a cancer). The two different cell types are co-cultured or otherwise allowed to interact with one another before and during exposure to the agent. The images of the cells show how the agent affects the cells' phenotypes, including their viability, migration patterns, etc. The method generates a quantitative phenotype for each cell type by quantitatively analyzing the cell images via an automatic procedure. The quantitative phenotypes typically take the form of a group of scalar or vector descriptors that together provide a “fingerprint.” The descriptors may be size values, positions, morphological values, intensity distributions, etc.
    Type: Application
    Filed: February 20, 2002
    Publication date: August 29, 2002
    Applicant: Cytokinetics, Inc., a Delaware Corporation
    Inventor: Kathleen A. Elias
  • LOW MOLECULAR WEIGHT PEPTIDOMIMETIC GROWTH HORMONE SECRETAGOGUES
    Publication number: 20020111461
    Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.
    Type: Application
    Filed: May 21, 1999
    Publication date: August 15, 2002
    Inventors: TODD C. SOMERS, KATHLEEN A. ELIAS, ROSS G. CLARK, ROBERT S. MCDOWELL, MARK S. STANLEY, JOHN P. BURNIER, THOMAS E. RAWSON
  • Low molecular weight peptidomimetic growth hormone secretagogues
    Patent number: 6034216
    Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.
    Type: Grant
    Filed: April 8, 1998
    Date of Patent: March 7, 2000
    Assignee: Genentech Inc.
    Inventors: Todd C. Somers, Kathleen A. Elias, Ross G. Clark, Robert S. McDowell, Mark S. Stanley, John P. Burnier, Thomas E. Rawson